Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT04500561

YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial

YY-20394 Combined With GEMOX in the Treatment of Patients With Relapsed and/or Refractory Diffuse Large B-cell Lymphoma With a Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial

Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd.

Conditions Diffuse Large B Cell Lymphoma

Interventions YY-20394

Updated 5 times since 2020 Last updated: Aug 3, 2020 Started: Aug 20, 2020 Primary completion: Oct 1, 2021 Completion: Dec 1, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Diffuse Large B Cell Lymphoma and is currently ongoing. Shanghai YingLi Pharmaceutical Co. Ltd. leads this study, which shows 5 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Sep 2022 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Sep 2022 [monthly]

Not Yet Recruiting PHASE1_PHASE2
Sep 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Aug 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai YingLi Pharmaceutical Co. Ltd.

Data source: Shanghai YingLi Pharmaceutical Co. Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.